226 related articles for article (PubMed ID: 36520013)
1. Emerging Strategies of Engineering and Tracking Dendritic Cells for Cancer Immunotherapy.
Gao Y; Wang Z; Cui Y; Xu M; Weng L
ACS Appl Bio Mater; 2023 Jan; 6(1):24-43. PubMed ID: 36520013
[TBL] [Abstract][Full Text] [Related]
2. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells.
Bol KF; Schreibelt G; Rabold K; Wculek SK; Schwarze JK; Dzionek A; Teijeira A; Kandalaft LE; Romero P; Coukos G; Neyns B; Sancho D; Melero I; de Vries IJM
J Immunother Cancer; 2019 Apr; 7(1):109. PubMed ID: 30999964
[TBL] [Abstract][Full Text] [Related]
3. The role of dendritic cells in cancer immunity and therapeutic strategies.
Tai Y; Chen M; Wang F; Fan Y; Zhang J; Cai B; Yan L; Luo Y; Li Y
Int Immunopharmacol; 2024 Feb; 128():111548. PubMed ID: 38244518
[TBL] [Abstract][Full Text] [Related]
4. Nanotechnology-based manipulation of dendritic cells for enhanced immunotherapy strategies.
Klippstein R; Pozo D
Nanomedicine; 2010 Aug; 6(4):523-9. PubMed ID: 20085824
[TBL] [Abstract][Full Text] [Related]
5. Dendritic cells in cancer immunology and immunotherapy.
Wculek SK; Cueto FJ; Mujal AM; Melero I; Krummel MF; Sancho D
Nat Rev Immunol; 2020 Jan; 20(1):7-24. PubMed ID: 31467405
[TBL] [Abstract][Full Text] [Related]
6. Dendritic Cells and Cancer Immunotherapy: The Adjuvant Effect.
Nava S; Lisini D; Frigerio S; Bersano A
Int J Mol Sci; 2021 Nov; 22(22):. PubMed ID: 34830221
[TBL] [Abstract][Full Text] [Related]
7. Engineered exosomes as an in situ DC-primed vaccine to boost antitumor immunity in breast cancer.
Huang L; Rong Y; Tang X; Yi K; Qi P; Hou J; Liu W; He Y; Gao X; Yuan C; Wang F
Mol Cancer; 2022 Feb; 21(1):45. PubMed ID: 35148751
[TBL] [Abstract][Full Text] [Related]
8. Dendritic cells and cytokines in immune rejection of cancer.
Ferrantini M; Capone I; Belardelli F
Cytokine Growth Factor Rev; 2008 Feb; 19(1):93-107. PubMed ID: 18054517
[TBL] [Abstract][Full Text] [Related]
9. Immune adjuvants as critical guides directing immunity triggered by therapeutic cancer vaccines.
Schijns V; Tartour E; Michalek J; Stathopoulos A; Dobrovolskienė NT; Strioga MM
Cytotherapy; 2014 Apr; 16(4):427-39. PubMed ID: 24280238
[TBL] [Abstract][Full Text] [Related]
10. Dendritic cell vaccines in breast cancer: Immune modulation and immunotherapy.
Qian D; Li J; Huang M; Cui Q; Liu X; Sun K
Biomed Pharmacother; 2023 Jun; 162():114685. PubMed ID: 37058818
[TBL] [Abstract][Full Text] [Related]
11. Potential approaches for more successful dendritic cell-based immunotherapy.
Chiang CL; Balint K; Coukos G; Kandalaft LE
Expert Opin Biol Ther; 2015 Apr; 15(4):569-82. PubMed ID: 25553913
[TBL] [Abstract][Full Text] [Related]
12. Engineering Dendritic-Cell-Based Vaccines and PD-1 Blockade in Self-Assembled Peptide Nanofibrous Hydrogel to Amplify Antitumor T-Cell Immunity.
Yang P; Song H; Qin Y; Huang P; Zhang C; Kong D; Wang W
Nano Lett; 2018 Jul; 18(7):4377-4385. PubMed ID: 29932335
[TBL] [Abstract][Full Text] [Related]
13. IFN-alpha in the generation of dendritic cells for cancer immunotherapy.
Santini SM; Lapenta C; Santodonato L; D'Agostino G; Belardelli F; Ferrantini M
Handb Exp Pharmacol; 2009; (188):295-317. PubMed ID: 19031032
[TBL] [Abstract][Full Text] [Related]
14. Engineering dendritic cell vaccines to improve cancer immunotherapy.
Perez CR; De Palma M
Nat Commun; 2019 Nov; 10(1):5408. PubMed ID: 31776331
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant for vaccine immunotherapy of cancer--focusing on Toll-like receptor 2 and 3 agonists for safely enhancing antitumor immunity.
Seya T; Shime H; Takeda Y; Tatematsu M; Takashima K; Matsumoto M
Cancer Sci; 2015 Dec; 106(12):1659-68. PubMed ID: 26395101
[TBL] [Abstract][Full Text] [Related]
16. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
[TBL] [Abstract][Full Text] [Related]
17. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses.
Du YC; Lin P; Zhang J; Lu YR; Ning QZ; Wang Q
Tissue Antigens; 2006 May; 67(5):368-76. PubMed ID: 16671943
[TBL] [Abstract][Full Text] [Related]
18. Turbocharging vaccines: emerging adjuvants for dendritic cell based therapeutic cancer vaccines.
Saxena M; Bhardwaj N
Curr Opin Immunol; 2017 Aug; 47():35-43. PubMed ID: 28732279
[TBL] [Abstract][Full Text] [Related]
19. Dendritic cell-based immunotherapy: a basic review and recent advances.
Constantino J; Gomes C; Falcão A; Neves BM; Cruz MT
Immunol Res; 2017 Aug; 65(4):798-810. PubMed ID: 28660480
[TBL] [Abstract][Full Text] [Related]
20. Dendritic cell biology and its role in tumor immunotherapy.
Wang Y; Xiang Y; Xin VW; Wang XW; Peng XC; Liu XQ; Wang D; Li N; Cheng JT; Lyv YN; Cui SZ; Ma Z; Zhang Q; Xin HW
J Hematol Oncol; 2020 Aug; 13(1):107. PubMed ID: 32746880
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
